Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of TherapyBusiness Wire • 02/23/24
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 ResultsBusiness Wire • 02/13/24
GenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare SectorPRNewsWire • 01/04/24
Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3Business Wire • 01/03/24
Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/02/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Legend Biotech Corporation - LEGNPRNewsWire • 12/19/23
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)Business Wire • 12/12/23
Legend Biotech highlights Novartis deal worth up to $1.11BN alongside 3Q resultsProactive Investors • 11/20/23
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most OnThe Motley Fool • 11/16/23
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3Business Wire • 11/13/23
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual MeetingBusiness Wire • 11/02/23